A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density
Latest Information Update: 04 Nov 2024
At a glance
- Drugs Blosozumab (Primary)
- Indications Osteoporosis
- Focus Adverse reactions
Most Recent Events
- 28 Apr 2022 Status changed from planning to recruiting, according to a Transcenta Holding media release.
- 22 Sep 2021 According to a Transcenta Holding media release, the company announced that it received IND clearance rom NMPA for initiating Phase I clinical trial of TST002.
- 12 Jul 2021 New trial record